Provided by Tiger Fintech (Singapore) Pte. Ltd.

Solid Biosciences

3.45
-0.2550-6.89%
Post-market: 3.450.0050+0.15%18:23 EDT
Volume:1.86M
Turnover:6.59M
Market Cap:266.96M
PE:-1.13
High:3.77
Open:3.76
Low:3.43
Close:3.70
Loading ...

Company Profile

Company Name:
Solid Biosciences
Exchange:
NASDAQ
Establishment Date:
2013
Employees:
100
Office Location:
500 Rutherford Avenue,Third Floor,Charlestown,Massachusetts,United States
Zip Code:
02129
Fax:
- -
Introduction:
Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Directors

Name
Position
Andrey Zarur
Co-Founder and Chairman of the Board
Ilan Ganot
Co-Founder, President, Chief Executive Officer and Director
Adam Koppel
Independent Director
Adam Stone
Independent Director
Ian F. Smith
Director, Consultant
Lynne Sullivan
Independent Director
Martin Freed
Independent Director
Matthew Arnold
Independent Director
Rajeev Shah
Independent Director
Robert Huffines
Independent Director
Sukumar Nagendran
Independent Director

Shareholders

Name
Position
Ilan Ganot
Co-Founder, President, Chief Executive Officer and Director
Jennifer Ziolkowski
Chief Financial Officer and Treasurer
Carl Morris
Chief Scientific Officer
Joel Schneider
Chief Technology Officer
Lynette Herscha
Chief Legal Officer and Secretary